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A mutual interplay exists between adaptive immune system and gut microbiota. Altered
gut microbial ecosystems are associated with the metabolic syndrome, occurring in
most obese individuals. However, it is unknown why 10–25% of obese individuals are
metabolically healthy, while normal weight individuals can develop inflammation and
atherosclerosis. We modeled these specific metabolic conditions in mice fed with a chow
diet, an obesogenic but not inflammatory diet—mimicking healthy obesity, or Paigen
diet—mimicking inflammation in the lean subjects. We analyzed a range of markers and
cytokines in the aorta, heart, abdominal fat, liver and spleen, andmetagenomics analyses
were performed on stool samples. T lymphocytes infiltration was found in the aorta and
in the liver upon both diets, however a significant increase in CD4+ and CD8+ cells
was found only in the heart of Paigen-fed animals, paralleled by increased expression of
IL-1, IL-4, IL-6, IL-17, and IFN-γ. Bacteroidia, Deltaproteobacteria, and Verrucomicrobia
dominated in mice fed Paigen diet, while Gammaproteobacteria, Delataproteobacteria,
and Erysipelotrichia were more abundant in obese mice. Mice reproducing human
metabolic exceptions displayed gut microbiota phylogenetically distinct from normal
diet-fed mice, and correlated with specific adaptive immune responses. Diet composition
thus has a pervasive role in co-regulating adaptive immunity and the diversity of
microbiota.
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INTRODUCTION
The main feature of obesity is an excess of adipose tissue, which is the result of an imbalance
existing between the intake and the expenditure of energy. The causes of obesity are both genetic
and environmental; the diseases often comes along with the establishment of several chronic
co-morbidities, such as high fasting hyperglycaemia, hypertriglyceridemia, dyslipidaemia, and
hypertension (Alberti et al., 2005). Clinical diagnosis of metabolic syndrome is defined by the co-
presence of at least three of the above criteria (Alberti et al., 2005). Metabolic syndrome enhances
the odds of having type 2 diabetes and of developing diseases of the cardiovascular system. The
majority of people with the metabolic syndrome are in obese, suggesting that the excess mass of
adipose tissue may play a causative role in this cluster of diseases (Despres et al., 2008). However,
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this hypothesis has been strongly debated because several
epidemiological analyses have evidenced people with a normal
body mass index (BMI) who nevertheless display markers of
inflammation and metabolic diseases [here termed metabolic
syndrome leans (MSL)], such as high levels of triglycerides and
accumulation of fat in the liver (Alberti et al., 2005); in fact,
independently of BMI, and with variability linked to race and
geographical areas, approximately 1 adult in every 4 or 5 had
metabolic syndrome (Alberti et al., 2005). Conversely, a lack
of clinical consistency for several or all metabolic syndrome
components is found in some individuals with long-established
and morbid obesity, which is actually recognized as healthy
despite a high BMI. These subjects are referred to asmetabolically
healthy obese (MHO), and their prevalence has been estimated to
be between 10 and 40% of the obese population, notwithstanding
design differences between studies, such as age, ethnicity,
geography, sample size, and the lack of a standardization
(Munoz-Garach et al., 2016). As the prevalence of obesity
and metabolic syndrome rises continuously with enormous
FIGURE 1 | (A) Pie chart representing diet compositions in terms of fat, carbohydrates, choline, cholesterol, proteins. (B) Body weight of C57/BL6 mice fed for 20
weeks with a normal chow diet (ND), high fat diet (HD), or Paigen diet (PD). (C) Representative pictures from hematoxylin and eosin staining of liver sections (upper
panels) and aorta sections (lower panels) in C57/BL6 mice fed with ND, HD, or PD. (D) Steatosis, lobular inflammation, and ballooning were scored semi quantitatively
(0–4). *p < 0.05; **p < 0.01; ***p < 0.001 vs. ND.
economic and social costs, innovative countermeasures on
the biological mechanisms, beyond prevention and lifestyle
interventions, are required. In particular, the biological and
disease mechanisms underlying the pathology of MSL and the
health of MHO are not understood. Inflammation has been
persistently associated with both obesity-associated diseases and
the metabolic syndrome, indicating that low-grade inflammation
is a potential and modifiable risk factor (Cox et al., 2015).
The gut microbiota can be considered a distinct organ with
endocrine properties; gut microbiota is involved, through a tight
molecular interplay with the host organism, in the homeostasis
of host organism energy and in stimulating of its immune system
(Clarke et al., 2014). It has been proposed that gut microbiota
participates to the establishment of metabolic diseases via the
onset of low-grade inflammatory processes (Zupancic et al.,
2012; Marchesi et al., 2016), and its composition is rapidly and
heavily modulated by the diet (David et al., 2014). However,
under healthy conditions commensal bacteria colonizing the
gut interplay with the host immunity to maintain a state of
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homeostasis. In this respect, an immune system–gut microbiota
cooperation which operates at optimal levels is instrumental
for setting protective mechanisms against pathogenic agents
and, at the same time, for keeping in check the regulatory
pathways implicated in the avoidance of triggering immune
responses to harmless antigens (Belkaid and Hand, 2014). This
reciprocal interaction involves both innate (Thaiss et al., 2014)
and adaptive immunity (Kato et al., 2014; Zhang and Luo, 2015).
In this respect, signals from gut microbiome play crucial role in
maturation (or differentiation) of IL-17 expressing Th17 cells as
well as IFN-γ expressing Th1 cells (Ivanov et al., 2008; Gaboriau-
Routhiau et al., 2009). Although, it has been suggested that
dysbiosis can cause immune dysfunctions by activating B and
T cells regardless of their distance from the location of their
induction (Honda and Littman, 2016), there is scarce knowledge
on the relationship between distinct immune cell populations,
more in particular those belonging to the adaptive immunity,
and the heterogeneity of digestive system-residing and symbiotic
bacteria.
Here we modeled the metabolic and clinical features of MSL
andMHOhumans in C57/BL6mice fed for 20 weeks with a chow
diet, a high fat obesogenic but not inflammatory diet (mimicking
healthy obesity) or a hypercholesteraemic, pro-atherogenic, low
fat diet (Paigen diet, mimicking systemic inflammation, and
fatty liver in the lean subjects; Getz and Reardon, 2006), under
the same housing environment. We then analyzed possible
interactions among adaptive immune system in multiple tissues,
and gut microbiota. Mice fed these distinct “unhealthy” diets
reproducing human metabolic exceptions, MSL and MHO, had
a gut microbiota with phylogenetic characteristics significantly
divergent from normal diet-fed littermates, and displayed specific
intra-tissue adaptive immune responses.
MATERIALS AND METHODS
Dietary Mice Models
Four week old male C57BL/6 (B6) mice were purchased from
Velaz, Ltd. (Prague, Czech Republic). Animals (n = 10 per
experimental group) were housed in specific pathogen-free
facilities and fed ad libitum with basal (normal) or specific
(Paigen or Western) diet for 20 weeks with fresh, clean water
available at all time. Diet compositions were as following: normal
diet (ND): proteins % 18.6, fat % 10 (Linoleic Acid, % 3.34,
Linolenic Acid, % 0.07 Arachidonic Acid, % 0.01, Omega-3 FA,
% 0.07, Saturated FA % 2.72, Monounsaturated FA, % 3.31,
Polyunsaturated FA, % 3.42), carbohydrates % 60.6, cholesterol
% 0, choline chloride % 0; High fat diet (HD): proteins %
17.3, fat % 21.2 (Linoleic Acid, % 1.70, Linolenic Acid, % 0.16
FIGURE 2 | Metabolic parameters of C57BL/6 mice fed a standard normal chow (ND) or a high fat diet (HD) or a Paigen diet (PD) for 15 weeks. (A) fasting glucose;
(B) fasting insulin; (C) serum triglycerides; (D) serum cholesterol. N = 4. *p < 0.05, **p < 0.01, ***p < 0.001 vs. ND; #p < 0.05, ##p < 0.01 vs. HD.
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FIGURE 3 | (A) Cell suspension obtained from tissues were surface-stained for T lymphocyte markers with antibody combination CD45, CD4, and CD8 (A) and gated
for CD45+ CD4+ T lymphocytes and CD45+ CD8+ T lymphocytes. (B) For myeloid cell subsets, the cell suspensions were surface-stained with antibody against
CD45, CD11b, CD11c, Ly6G, and F4/80 (B) and gated for CD45+ CD11b+ Ly6G+ neutrophils, CD45+ CD11b+ CD11c+ dendritic cells, CD45+ CD11b+ CD11c-
F4/80+ macrophages.
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Arachidonic Acid, % 0.02 Omega-3 FA, % 0.23, Saturated FA,
% 7.92 Monounsaturated FA, 6.28, Polyunsaturated FA, % 3.14),
carbohydrate % 48.5, cholesterol % 0, choline chloride % 0.2);
Paigen diet (PD): proteins % 20.8, fat % 15 (Linoleic Acid, %
1.70, Linolenic Acid, % 0.14, Arachidonic Acid, % 0.01, Omega-3
FA, % 0.16, Saturated FA % 7.18 Monounsaturated FA, % 5.34,
Polyunsaturated FA, % 1.91), carbohydrate % 61, cholesterol %
1.25, choline chloride % 0.5. The experiments were performed
in accordance with the law governing the protection of animals
and the principles derived from the requirements of the Act
No. 359/2012 Sb., on the protection of animals against cruelty
and the decree 419/2012 Sb. Ministry of Agriculture of Czech
Republic on the protection of experimental animals (including
relevant EU regulations). The experiments were approved by the
local Animal Ethics Committee on the Welfare of Experimental
Animals and by the Ministry of Education of Czech Republic
(MSMT-2582/2016-14)—project number 66-2015. Serum levels
of fasting glucose, fasting insulin, triglycerides, and cholesterol
were measured as we have previously described (Cederroth et al.,
2008; Pazienza et al., 2016).
Histology
Samples of liver, aorta, and heart from eachmouse and were fixed
in formalin and embedded in paraffin for histological analysis.
Sections with a thickness of 4 µm were obtained from paraffin
blocks and stained with hematoxylin and eosin for histological
examinations (Benegiamo et al., 2013). Histological classification
of NAFLD was performed by applying a semiquantitative
scoring system grouping histological traits into broad classes
(steatosis, fibrosis, portal inflammation, hepatocellular injury,
and miscellaneous features; Kleiner et al., 2005).
Tissue Digestion and Single Cell
Suspension Preparation
To prepare single cell suspension from solid tissue (aorta, heart,
and abdominal fat), required digestion, the tissue was minced
with a sterile scissors and placed in 1 ml DMEM containing:
for heart and aorta—2.5 mg/ml Collagenase type XI, 0.25 mg/ml
Hyaluronidase type I-s, 0.25 mg/ml DNase I, 2.5mg Collagenase
type I; for abdominal fat−1mg/ml Collagenase IV of 3%DMEM.
Tissues were incubated in water bath for 1 h with vortex every
FIGURE 4 | Immune cells profiling in the tissues of Normal diet (ND)-, High fat diet (HD)-, and Paigen diet (PD)-fed mice. Single cell suspensions were prepared from
solid tissues (aorta, heart, and liver) and processed for FACS analyses. Combination of surface markers for T-lymphocytes was CD45, CD4, and CD8 and myeloid
cells were stained for CD45, CD11b, CD11c, F4/80, and Ly6G. (A) Frequency of total myeloid cells and cells positive gated for CD45, CD11b, CD11c, F4/80, and
Ly6G in the spleen. (B) Frequency of lymphocytes in the aorta and in the liver, of gated cells. (C) Frequency of cells gated for CD4 and CD8 in the aorta and in the
heart. N = 3.4. *p < 0.05; **p < 0.01.
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15 min and washed by cold PBS. Erythrocytes were removed
by RBC lysis buffer (Biolegend), cells were washed by PBS and
transferred to fresh tubes through 70mmnylonmesh. Finally, the
cell suspension was resuspended in 1 ml PBS per sample. Spleen
and liver were cut into small pieces and passed through tissue
grinder to Petri dish, and then the cell suspension was passed
through the 70 µm cell strainers and processed as mentioned
above. Peripheral blood was collected into heparinized syringe,
resuspend in PBS and spin down. Erythrocytes were removed by
RBC lysis buffer and cells passed through the 70 µm cell strainer.
Single cell suspensions were used for flow cytometry or PCR.
Flow Cytometry
Cells in single cell suspensions were stained in 100 µl aliquots
of FACS buffer (2% FBS in PBS) after incubation with
fluorochrome-labeled antibodies for 30 min at 4◦C followed by
washing in FACS buffer. Combination of surface markers for T-
lymphocytes was CD45, CD4, and CD8 and myeloid cell subsets
were stained for CD45, CD11b, CD11c, F4/80, and Ly6G using
specific antibodies (Biolegend). Analysis was performed using
a BD Biosciences FACSCanto R© flow cytometer and FlowJo R©
software (TreeStar Inc., Olten, Switzerland).
Gene Expression
Total RNA was isolated from cell suspensions using Trizol LS
Reagent (Life Technologies). RNA was converted to cDNA
using gb Reverse Transcription Kit (Generi-Biotech, Czech
Republic). Equal amounts of cDNA were analyzed by Real-Time
quantitative PCR using gb Elite PCR Master Mix (Generi-
Biotech, Czech Republic) on a LightCycler R© 480 Real Time
PCR System (Roche). Relative quantifications were performed
using the comparative CT method with normalization to
GAPDH and results expressed as fold difference relative to a
relevant control sample. Primers and probes were from Qiagen:
GAPDH (Mm99999915_g1), IL-17A (Mm00439618_m1),
IFN-γ (Mm01168134_m1), IL-4 (Mm00445259_m1), TGF-
β (Mm01178820_m1), IL-6 (Mm00446190_m1), IL-12 p35
(Mm00434165_m1).
Metagenomics Profiling
The microbial population present in the fecal samples from
mice was determined using next generation high throughput
sequencing of variable regions of the 16S rRNA bacterial
gene. The workflow performed at VAIOMER (France) includes
the steps of (i) Library construction and sequencing; (ii)
FIGURE 5 | Cytokine gene expression in the tissues of Normal diet (ND)-, High fat diet (HD)-, and Paigen diet (PD)-fed mice. Single cell suspensions were prepared
from solid tissues (aorta, heart, and abdominal fat), and used for total RNA extraction and for qPCR. Relative quantification of IL-17A, IFN-γ, IL-4, TGF-β, IL-1α, IL-12,
and IL-6 mRNA levels were performed using the comparative CT method with normalization to GAPDH; results were expressed as fold difference relative to a relevant
control sample. (A) IL-17 mRNA levels in the aorta, heart and adipose tissue. (B) IFN-γ and IL-4 mRNA levels in the aorta. (C) IL-1α, IFN-γ, and IL-4 mRNA levels in
the heart. (D) IL-6 and IL-12 mRNA levels in the adipose tissue. N = 3–4. *p < 0.05; **p < 0.01.
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PCR amplification was performed using 16S universal primers
targeting the V3–V4 region of the bacterial 16S ribosomal
gene (Vaiomer universal 16S primers). The joint pair length
was set to encompass 476 base pairs amplicon thanks to 2 ×
300 paired-end MiSeq kit V3. For each sample, a sequencing
library was generated by addition of sequencing adapters. The
FIGURE 6 | (A) Alpha diversity using Shannon index of the fecal microbiota for
each groups. (B) Relative abundance of major Phylum (Bacteroidetes and
Firmicutes) for each group. (C) Relative abundance of most significant species,
using RDP v11.4 databank in fecal samples of ND, HD, or PD mice. Graphs
are displayed as mean ± SEM. **p < 0.01; ***p < 0.001, One-Way Anova
followed by Kruskal–Wallis test.
detection of the sequencing fragments was performed using
MiSeq Illumina R© technology; (iii) Bioinformatics pipeline, The
targeted metagenomic sequences from microbiota were analyzed
using the bioinformatics pipeline established by Vaiomer from
the FROGS v1.3.0 guidelines. Briefly, after demultiplexing of
the bar coded Illumina paired reads, single read sequences are
cleaned and paired for each sample independently into longer
fragments. Operational taxonomic units (OTU) are produced
via single-linkage clustering and taxonomic assignment is
performed in order to determine community profiles. PhyloSeq
v1.14.0 R package was used to provide a set of classes and
tools to facilitate the import, storage, analysis, and graphical
display of microbiome census data. The samples with <5,000
sequences after FROGS processing were not included in the
statistics (rarefaction analysis, alpha diversity, beta diversity-
multidimensional scaling). The raw sequencing data are available
upon request.
LEfSe Method
The OTU files generated were uploaded and formatted for LEfSe
analysis using the per sample normalization of sum values option.
The linear discriminant analysis effect size was determined using
default values (alpha value of 0.5 for both the factorial Kruskal–
Wallis test among classes and the pairwiseWilcoxon test between
subclasses, threshold of 2.0 for the logarithmic LDA score for
discriminative features) and the strategy for multi-class analysis
set to “allagainst-all.” LEfSe cladograms from the LDS effect size
data were generated with Bacteria as the tree root. Differential
features detected as biomarkers from the raw data used to
generate the cladograms were plotted as abundance histograms
with class and subclass information.
Statistical Methods
The parametric Student’s t-test (2-sample t-test) was used to
compare the difference in mean of immune cells by type of diet
(HD vs. ND), and difference in mean of cytokines by type of diet
(HD vs. ND). The non-parametric Mann–Whitney U-test was
also used to check if the results were basically similar to the t-
test using GraphPad Prism Software (version 5.00 for Windows,
San Diego, CA, USA): a p < 0.05 was considered significant.
To explore the association of gut microbiota with immune
cells and cytokines levels, analyses were carried out using
STATA/SE software. As preliminary analysis, mean and standard
deviation (SD) of each gut microbiota type and adaptive immune
system parameters measured in the aorta, heart, liver, spleen,
and fat were calculated. The Pearson’s correlations between
each gut microbiota and adaptive immune system parameters
were also examined. In the final analysis, associations between
gut microbiota and adaptive immune system parameters levels
were explored by using linear regression models. In each of
the models, the associations between each bacterial taxa and
adaptive immune system parameters were reported as absolute
difference (β), with 95% Confidence Intervals (CI), in immune
system parameters levels by % of increase in the proportion of
the bacterial taxa. Coefficient of determination (R2) was also
reported.
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FIGURE 7 | Gut microbiota profiling in Normal diet (ND)-, High fat diet (HD)-, and Paigen diet (PD)-fed mice. (A) Multi Dimentional Scaling (MSD) of Unifrac distances
of the fecal microbiota for each groups. (B) Hierarchical clustering of Unifrac distances of the fecal microbiota for each groups. (C,D) Relative abundance of Phylum
and Family, respectively for each fecal sample. (E) Cladogram representing taxa enriched in fecal samples of ND, HD, or PD mice detected by the LEfSe tool. (F)
Relative abundance of most significant taxa in fecal samples of ND, HD, or PD mice. Graphs are displayed as mean ± SEM.
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TABLE 1 | Associations from linear models between gut microbiota and alterations of adaptive immune system parameters measured in the Aorta.
IL-17 IFNg IL-4 TGFb IL-6 Lymphocytes CD45+ CD4+ CD8+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Actinobacteria −2.0 −1.7 −1.0 −32.5 −8.9 35.7 25.2 −30.2 −16.5
(−6.1, 2.1) (−7.0, 3.5) (−3.1, 1.0) (−101.3, 36.3) (−24.2, 6.5) (−84.2, 155.5) (−85.6, 136.1) (−63.5, 3.1) (−42.8, 9.8)
p = 0.287 p = 0.459 p = 0.271 p = 0.301 p = 0.214 p = 0.526 p = 0.626 p = 0.071 p = 0.195
R2 = 0.159 R2 = 0.081 R2 = 0.169 R2 = 0.151 R2 = 0.211 R2 = 0.037 R2 = 0.022 R2 = 0.290 R2 = 0.147
Alphaproteobacteria 0.1 0.1 0.1 −6.0 0.4 7.8 6.9 0.6 0.8
(−0.6, 0.8) (−0.7, 1.0) (−0.3, 0.4) (−16.5, 4.5) (−2.3, 3.1) (−11.8, 27.5) (−11.2, 25.0) (−5.1, 6.2) (−3.9, 5.5)
p = 0.815 p = 0.727 p = 0.624 p = 0.219 p = 0.725 p = 0.399 p = 0.417 p = 0.833 p = 0.715
R2 = 0.008 R2 = 0.018 R2 = 0.036 R2 = 0.207 R2 = 0.019 R2 = 0.066 R2 = 0.061 R2 = 0.005 R2 = 0.013
Bacilli −0.1 −0.1 −0.0 −1.3 −0.2 −2.1 −2.0 −1.8 −1.6
(−0.7, 0.5) (−0.8, 0.6) (−0.3, 0.3) (−11.5, 8.8) (−2.6, 2.1) (−19.5, 15.3) (−18.0, 14.0) (−6.6, 2.9) (−5.5, 2.4)
p = 0.642 p = 0.753 p = 0.876 p = 0.764 p = 0.837 p = 0.795 p = 0.791 p = 0.412 p = 0.405
R2 = 0.033 R2 = 0.015 R2 = 0.004 R2 = 0.014 R2 = 0.006 R2 = 0.006 R2 = 0.007 R2 = 0.068 R2 = 0.064
Bacteroidia 0.07 0.09 0.03 −0.5 0.2 0.5 0.3 0.5 0.4
(0.02, 0.12) (0.02, 0.15) (0.00, 0.06) (−1.8, 0.8) (0.0, 0.5) (−1.4, 2.5) (−1.5, 2.1) (−0.0, 0.9) (0.0, 0.8)
p = 0.012 p = 0.018 p = 0.035 p = 0.370 p = 0.043 p = 0.564 p = 0.684 p = 0.055 p = 0.043
R2 = 0.615 R2 = 0.576 R2 = 0.492 R2 = 0.116 R2 = 0.465 R2 = 0.031 R2 = 0.016 R2 = 0.321 R2 = 0.323
Betaproteobacteria 7.6 8.3 3.2 9.4 24.4 41.4 30.5 38.5 35.1
(0.7, 14.6) (−1.1, 17.6) (−0.8, 7.2) (−154.1, 172.9) (−6.4, 55.2) (−139.0, 221.8) (−135.7, 196.8) (−5.2, 82.3) (−0.6, 70.7)
p = 0.036 p = 0.076 p = 0.103 p = 0.896 p = 0.104 p = 0.623 p = 0.694 p = 0.078 p = 0.053
R2 = 0.490 R2 = 0.382 R2 = 0.334 R2 = 0.003 R2 = 0.333 R2 = 0.023 R2 = 0.015 R2 = 0.278 R2 = 0.299
Clostridia −0.07 −0.09 −0.03 1.0 −0.3 −1.0 −0.8 −0.5 −0.4
(−0.13, −0.01) (−0.16, −0.02) (−0.10, −0.00) (−0.2, 2.2) (−0.5, 0.0) (−3.1, 1.1) (−2.7, 1.2) (−1.0, 0.1) (−0.9, −0.0)
p = 0.021 p = 0.020 p = 0.033 p = 0.094 p = 0.052 p = 0.305 p = 0.409 p = 0.073 p = 0.044
R2 = 0.554 R2 = 0.563 R2 = 0.500 R2 = 0.349 R2 = 0.440 R2 = 0.095 R2 = 0.063 R2 = 0.286 R2 = 0.319
Deferribacteres −1.7 −1.8 −0.6 23.0 −3.9 −45.0 −35.1 −18.8 −19.2
(−5.0, 1.7) (−6.0, 2.4) (−2.3, 1.2) (−35.6, 81.6) (−17.8, 10.1) (−142.6, 52.5) (−125.7, 55.6) (−45.1, 7.5) (−39.3, 1.0)
p = 0.285 p = 0.349 p = 0.483 p = 0.384 p = 0.533 p = 0.332 p = 0.413 p = 0.142 p = 0.060
R2 = 0.161 R2 = 0.126 R2 = 0.073 R2 = 0.110 R2 = 0.058 R2 = 0.086 R2 = 0.062 R2 = 0.202 R2 = 0.285
Deltaproteobacteria 0.2 0.4 0.2 −9.0 1.0 12.0 9.2 −1.3 −0.7
(−0.5, 0.9) (−0.4, 1.1) (−0.2, 0.5) (−17.3, −0.7) (−1.5, 3.5) (−3.6, 27.6) (−5.6, 24.1) (−6.7, 4.0) (−4.7, 3.4)
p = 0.496 p = 0.298 p = 0.267 p = 0.037 p = 0.364 p = 0.120 p = 0.198 p = 0.594 p = 0.722
R2 = 0.069 R2 = 0.153 R2 = 0.172 R2 = 0.485 R2 = 0.118 R2 = 0.205 R2 = 0.146 R2 = 0.029 R2 = 0.012
Erysipelotrichia −1.0 −1.0 −0.3 −16.5 −3.2 32.6 31.2 −6.6 −4.0
(−3.4, 1.5) (−4.1, 2.0) (−1.6, 0.9) (−57.5, 24.5) (−12.8, 6.5) (−39.8, 105.1) (−35.0, 97.4) (−28.2, 14.9) (−21.5, 13.4)
p = 0.377 p = 0.460 p = 0.557 p = 0.373 p = 0.465 p = 0.342 p = 0.322 p = 0.507 p = 0.621
R2 = 0.113 R2 = 0.080 R2 = 0.051 R2 = 0.114 R2 = 0.079 R2 = 0.082 R2 = 0.089 R2 = 0.045 R2 = 0.023
Gammaproteobacteria 3.5 4.9 −1.9 −118.3 −21.9 106.9 71.4 −28.1 −4.8
(−11.1, 18.0) (−12.8, 22.6) (−9.2, 5.4) (−345.4, 108.7) (−76.3, 32.4) (−106.6, 320.4) (−129.6, 272.3) (−88.3, 32.1) (−57.2, 47.6)
p = 0.590 p = 0.534 p = 0.558 p = 0.257 p = 0.372 p = 0.294 p = 0.451 p = 0.324 p = 0.845
R2 = 0.044 R2 = 0.058 R2 = 0.051 R2 = 0.178 R2 = 0.115 R2 = 0.100 R2 = 0.053 R2 = 0.097 R2 = 0.004
Mollicutes −0.2 −0.3 −0.1 5.6 −0.7 −14.9 −12.5 −1.7 −2.2
(−0.7, 0.2) (−0.9, 0.3) (−0.4, 0.1) (−1.5, 12.7) (−2.6, 1.2) (−25.9, −3.9) (−23.3, −1.7) (−5.7, 2.3) (−5.3, 0.9)
p = 0.298 p = 0.269 p = 0.276 p = 0.105 p = 0.414 p = 0.013 p = 0.027 p = 0.370 p = 0.150
R2 = 0.153 R2 = 0.171 R2 = 0.167 R2 = 0.331 R2 = 0.097 R2 = 0.445 R2 = 0.370 R2 = 0.081 R2 = 0.179
(Continued)
Frontiers in Microbiology | www.frontiersin.org 9 June 2017 | Volume 8 | Article 1157
Pindjakova et al. Gut Dysbiosis and Adaptive Immunity
TABLE 1 | Continued
IL-17 IFNg IL-4 TGFb IL-6 Lymphocytes CD45+ CD4+ CD8+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Multi-affiliation −1.4 −1.5 −0.6 −9.2 −4.8 10.2 7.2 −0.6 0.9
(−3.5, 0.7) (−4.2, 1.2) (−1.7, 0.6) (−49.7, 31.3) (−13.3, 3.7) (−20.9, 41.3) (−21.6, 36.0) (−9.4, 8.3) (−6.5, 8.3)
p = 0.161 p = 0.236 p = 0.270 p = 0.608 p = 0.220 p = 0.484 p = 0.595 p = 0.891 p = 0.799
R2 = 0.260 R2 = 0.193 R2 = 0.170 R2 = 0.040 R2 = 0.206 R2 = 0.045 R2 = 0.026 R2 = 0.002 R2 = 0.006
Negativicutes 2.1 2.7 −0.3 −32.4 −4.2 52.8 35.8 2.3 8.4
(−2.6, 6.7) (−3.0, 8.3) (−2.8, 2.2) (−111.5, 46.8) (−23.2, 14.9) (−87.0, 192.6) (−94.3, 165.9) (−45.7, 50.3) (−24.7, 41.6)
p = 0.332 p = 0.297 p = 0.792 p = 0.366 p = 0.622 p = 0.423 p = 0.557 p = 0.918 p = 0.587
R2 = 0.134 R2 = 0.154 R2 = 0.011 R2 = 0.118 R2 = 0.037 R2 = 0.059 R2 = 0.032 R2 = 0.001 R2 = 0.028
Verrucomicrobiae 0.5 0.6 0.2 −6.4 1.5 14.9 13.8 6.4 5.5
(0.1, 1.0) (−0.0, 1.2) (−0.1, 0.5) (−16.2, 3.3) (−0.7, 3.8) (−0.3, 30.2) (−0.2, 27.8) (3.9, 8.9) (3.4, 7.7)
p = 0.027 p = 0.057 p = 0.100 p = 0.164 p = 0.147 p = 0.054 p = 0.052 p < 0.001 p < 0.001
R2 = 0.526 R2 = 0.425 R2 = 0.338 R2 = 0.257 R2 = 0.276 R2 = 0.297 R2 = 0.301 R2 = 0.761 R2 = 0.750
In each of the models, the associations are reported as absolute difference (β), with 95% Confidence Intervals (CI), in immune system parameters levels by 1 unit increase in gut
microbiota. In bold are reported the statistically significant results (p < 0.05). Per each of the models, the Coefficient of determination (R2 ) is also reported.
RESULTS
Modeling Healthy Obesity and Metabolic
Syndrome during Leanness in Mice
To model diets able to mimic MSL and MHO conditions in
humans, three groups (N = 10) of 4 weeks old C57/BL6 mice
were fed different dietary regimens: (i) a control normal diet (ND,
21.2% kcal from proteins, 58% kcal from carbohydrate, and 17%
from fat); (ii) high fat diet, rich in fatty acids (HD, 21.2% kcal
from proteins, 24% kcal from carbohydrate, and 58% from fat)
and with 0.1% cholesterol, and (iii) atherogenic/inflammatory
Paigen diet (PD), containing similar composition of the normal
diet with in addition 1.25% cholesterol and 0.5% sodium cholate
(Figure 1A). C57/BL6 mice had similar baseline weight before
starting being fed the diets (mean = ∼21 ± 0.4 g). After 15
weeks of dietary regimens, body weight was unchanged in mice
on the control ND or the PD, which both increased body weight
during growth by ∼33% (ND = 28.3 ± 0.7 g and PD = 28.8
± 0.77 g, respectively, Figure 1B). In contrast, mice on the HD
gained ∼65% in weight (HD = 35.9 ± 0.6 g), compared to their
baseline, indicating that only HD diet was obesogenic (p< 0.001
vs. ND and vs. PD). We then examined glucose and insulin
levels at the end of the dietary treatment. Basal insulin and
glucose fasting levels were considerably higher in PD vs. ND
and HD (Figures 2A,B). A similar trend was observed for serum
triglycerides and cholesterol levels, which were highest in the PD
group vs. ND and HD (Figures 2C,D). Obesogenic HD regimen
triggered lipid accumulation in the liver under the form of
simple steatosis, whereas atherogenic/inflammatory PD regimen
induced NAFLD/NASH at the end of its pathologic spectrum,
characterized by lipid accumulation, ballooning, fibrosis, and
inflammatory infiltrates, as quantified by NAFLD/NASH score
(Figure 1C upper panels, Figure 1D), consistent with previous
finding that the cholesterol and cholate components of Paigen
diet induces genes involved in inflammation and fibrosis,
respectively, in the liver (Vergnes et al., 2003). Cross-sectional
analysis of aortas walls suggested an increased infiltration of
inflammatory cells in the PD-fed mice, in comparison to ND
or HD fed mice (Figure 1C, lower panels). Altogether, these
data indicate that PD triggers prominent features of metabolic
syndrome and inflammation in mice in absence of weight gain,
compared to obesogenic HD.
Dissecting Diet-Dependent Intra-Tissue
Adaptive Immune Changes
Cells of the innate immune system, in particular macrophages,
mediate chronic inflammation (Sell et al., 2012). Moreover, B and
T lymphocytes of the adaptive immune system have been recently
recognized as important modulators of glucose homeostasis,
indicating that antigen-driven immune responses could influence
insulin resistance. Likemacrophages, lymphocytes can be divided
into populations with primarily proinflammatory functions
(including CD8+ cytotoxic T cells, Th1, Th17) or primarily
regulatory functions (including Treg or Th2) and the skewing
of the adaptive immune milieu toward a proinflammatory
phenotype can exacerbate the metabolic disturbances associated
to obesity (Nishimura et al., 2009; Winer et al., 2009; Shen et al.,
2015). Moreover, it is known since 1980 that T lymphocyte
subsets and related cytokines are present in atherosclerotic
lesions and affect their development (Lichtman, 2013). Here,
to analyze the changes of adaptive immunity between MSL
and MHO, we analyzed T cell populations from the blood
and the spleen (secondary lymphoid organ), from the heart
and the aorta (cardiovascular tissue), from the liver and from
the adipose tissue (metabolic and nutrient hubs) of ND, PD,
and HD-fed mice, using the flow cytometry gating strategy
depicted in Figure 2. Briefly, CD4+ and CD8+ T cells were
identified from the CD45+ lymphocyte populations, whereas to
study the myeloid lineage, CD11b+ subpopulation was further
analyzed for Ly6G+ cells (neutrophils), CD11b+CD11c+ cells
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TABLE 2 | Associations from linear regression models between gut microbiota and alterations of adaptive immune system parameters measured in the heart.
IL-17 IFNg IL-4 IL-1α IL-6 Lymphocytes CD45+ CD4+ CD8+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Actinobacteria −1.6 −1.8 −3 −1.5 −6 65 55.1 −30.9 −7.1
(−8.4, 5.2) (−4.7, 1.1) (−8.6, 2.5) (−4.9, 1.9) (−15.0, 3.0) (−39.7, 169.7) (−45.7, 156.0) (−58.7, −3.1) (−35.7, 21.5)
p = 0.602 p = 0.178 p = 0.201 p = 0.321 p = 0.157 p = 0.199 p = 0.254 p = 0.032 p = 0.597
R2 = 0.041 R2 = 0.243 R2 = 0.368 R2 = 0.140 R2 = 0.264 R2 = 0.145 R2 = 0.116 R2 = 0.353 R2 = 0.026
Alphaproteobacteria 0.1 0 −0.1 0 0.2 −1.1 3.4 0.4 1.1
(−1.0, 1.2) (−0.5, 0.6) (−1.1, 0.9) (−0.6, 0.5) (−1.4, 1.9) (−20.0, 17.7) (−14.3, 21.1) (−5.3, 6.2) (−3.7, 5.9)
p = 0.882 p = 0.900 p = 0.751 p = 0.848 p = 0.773 p = 0.896 p = 0.680 p = 0.879 p = 0.625
R2 = 0.003 R2 = 0.002 R2 = 0.028 R2 = 0.006 R2 = 0.013 R2 = 0.002 R2 = 0.016 R2 = 0.002 R2 = 0.022
Bacilli −0.1 −0.1 −0.2 −0.2 −0.2 2.9 1.9 −1.2 −0.3
(−1.1, 0.8) (−0.6, 0.3) (−1.0, 0.6) (−0.7, 0.2) (−1.7, 1.2) (−13.2, 19.0) (−13.5, 17.2) (−6.1, 3.7) (−4.4, 3.9)
p = 0.740 p = 0.570 p = 0.485 p = 0.283 p = 0.709 p = 0.697 p = 0.795 p = 0.597 p = 0.894
R2 = 0.017 R2 = 0.048 R2 = 0.129 R2 = 0.162 R2 = 0.021 R2 = 0.014 R2 = 0.006 R2 = 0.026 R2 = 0.002
Bacteroidia 0.1 0.1 0.2 0 0.2 −1.6 −0.6 0.6 0.3
(−0.0, 0.2) (0.0, 0.1) (0.1, 0.3) (−0.0, 0.1) (0.0, 0.3) (−3.1, −0.2) (−2.3, 1.1) (0.2, 1.0) (−0.1, 0.7)
p = 0.094 p = 0.011 p = 0.014 p = 0.053 p = 0.033 p = 0.034 p = 0.490 p = 0.009 p = 0.119
R2 = 0.349 R2 = 0.628 R2 = 0.814 R2 = 0.437 R2 = 0.501 R2 = 0.349 R2 = 0.044 R2 = 0.480 R2 = 0.207
Betaproteobacteria 8.1 5.9 8.1 6.1 16.7 −98.3 −28.3 58.5 12.5
(−5.3, 21.5) (0.8, 10.9) (−2.0, 18.1) (0.4, 11.9) (−0.7, 34.2) (−254.5, 57.8) (−187.4, 130.9) (24.4, 92.5) (−30.0, 55.0)
p = 0.196 p = 0.029 p = 0.090 p = 0.041 p = 0.058 p = 0.193 p = 0.703 p = 0.003 p = 0.531
R2 = 0.226 R2 = 0.518 R2 = 0.553 R2 = 0.473 R2 = 0.423 R2 = 0.149 R2 = 0.014 R2 = 0.564 R2 = 0.037
Clostridia −0.1 −0.1 −0.1 0 −0.2 1.7 0.5 −0.6 −0.4
(−0.2, 0.0) (−0.1, −0.0) (−0.3, 0.0) (−0.1, 0.0) (−0.3, −0.0) (0.1, 3.4) (−1.4, 2.4) (−1.1, −0.1) (−0.8, 0.1)
p = 0.095 p = 0.023 p = 0.086 p = 0.083 p = 0.045 p = 0.042 p = 0.544 p = 0.017 p = 0.113
R2 = 0.347 R2 = 0.547 R2 = 0.563 R2 = 0.369 R2 = 0.458 R2 = 0.324 R2 = 0.034 R2 = 0.417 R2 = 0.212
Deferribacteres −0.7 −1.1 4.5 −1.2 −3 34.3 −23.7 −15.9 −9.8
(−6.4, 5.1) (−3.7, 1.4) (−9.2, 18.2) (−4.1, 1.6) (−11.3, 5.3) (−57.5, 126.1) (−111.9, 64.5) (−42.8, 10.9) (−33.1, 13.5)
p = 0.789 p = 0.323 p = 0.411 p = 0.334 p = 0.424 p = 0.428 p = 0.566 p = 0.218 p = 0.375
R2 = 0.011 R2 = 0.139 R2 = 0.174 R2 = 0.133 R2 = 0.093 R2 = 0.058 R2 = 0.031 R2 = 0.134 R2 = 0.072
Deltaproteobacteria 0.7 0.2 0.7 0.2 0.5 −2.2 −6.5 −0.5 0.3
(−0.1, 1.6) (−0.3, 0.6) (−0.2, 1.5) (−0.4, 0.7) (−1.1, 2.0) (−18.4, 13.9) (−21.2, 8.3) (−5.4, 4.4) (−3.8, 4.5)
p = 0.074 p = 0.485 p = 0.086 p = 0.516 p = 0.490 p = 0.767 p = 0.356 p = 0.829 p = 0.870
R2 = 0.387 R2 = 0.072 R2 = 0.562 R2 = 0.063 R2 = 0.070 R2 = 0.008 R2 = 0.078 R2 = 0.004 R2 = 0.003
Erysipelotrichia −0.8 −0.8 −66.6 −0.7 −2 26.4 3.5 −8.8 −5.9
(−4.8, 3.2) (−2.6, 1.1) (−257.8, 124.7) (−2.7, 1.3) (−7.9, 3.8) (−41.5, 94.2) (−62.8, 69.8) (−29.4, 11.7) (−23.4, 11.7)
p = 0.636 p = 0.359 p = 0.389 p = 0.434 p = 0.436 p = 0.411 p = 0.910 p = 0.365 p = 0.477
R2 = 0.034 R2 = 0.121 R2 = 0.189 R2 = 0.090 R2 = 0.089 R2 = 0.062 R2 = 0.001 R2 = 0.075 R2 = 0.047
Gammaproteobacteria −5 −0.4 −5.3 −2.5 −11.9 4.1 35.4 −35.8 10.9
(−27.8, 17.9) (−11.5, 10.7) (−23.8, 13.2) (−14.5, 9.5) (−45.4, 21.7) (−204.5, 212.7) (−160.7, 231.6) (−94.8, 23.3) (−42.0, 63.8)
p = 0.624 p = 0.939 p = 0.473 p = 0.639 p = 0.430 p = 0.966 p = 0.699 p = 0.209 p = 0.659
R2 = 0.036 R2 = 0.001 R2 = 0.136 R2 = 0.033 R2 = 0.091 R2 = 0.000 R2 = 0.014 R2 = 0.139 R2 = 0.018
Mollicutes −0.3 −0.2 −0.3 −0.2 −0.5 3.9 1 −1.5 −1.1
(−1.1, 0.4) (−0.5, 0.2) (−1.1, 0.5) (−0.6, 0.2) (−1.6, 0.7) (−9.6, 17.4) (−12.0, 14.0) (−5.6, 2.6) (−4.5, 2.4)
p = 0.322 p = 0.329 p = 0.373 p = 0.398 p = 0.378 p = 0.540 p = 0.868 p = 0.433 p = 0.504
R2 = 0.140 R2 = 0.136 R2 = 0.201 R2 = 0.104 R2 = 0.113 R2 = 0.035 R2 = 0.003 R2 = 0.057 R2 = 0.042
(Continued)
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TABLE 2 | Continued
IL-17 IFNg IL-4 IL-1α IL-6 Lymphocytes CD45+ CD4+ CD8+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Multi-affiliation −1.3 −1.1 −4.9 −1.1 −3.2 6.7 5.6 0.4 −2.2
(−4.9, 2.4) (−2.6, 0.5) (−13.7, 3.9) (−2.8, 0.7) (−8.3, 1.8) (−22.5, 35.8) (−22.0, 33.3) (−8.6, 9.4) (−9.6, 5.2)
p = 0.443 p = 0.139 p = 0.196 p = 0.192 p = 0.177 p = 0.625 p = 0.662 p = 0.922 p = 0.527
R2 = 0.086 R2 = 0.285 R2 = 0.375 R2 = 0.230 R2 = 0.244 R2 = 0.022 R2 = 0.018 R2 = 0.001 R2 = 0.037
Negativicutes 1.3 0.8 0.1 1.3 −1.8 −68.7 35.8 −19.6 32.3
(−6.5, 9.0) (−2.9, 4.5) (−7.5, 7.8) (−2.7, 5.2) (−13.5, 10.0) (−194.3, 57.0) (−88.6, 160.1) (−58.3, 19.0) (5.7, 59.0)
p = 0.706 p = 0.629 p = 0.964 p = 0.470 p = 0.732 p = 0.254 p = 0.540 p = 0.287 p = 0.022
R2 = 0.022 R2 = 0.035 R2 = 0.001 R2 = 0.077 R2 = 0.018 R2 = 0.116 R2 = 0.035 R2 = 0.102 R2 = 0.394
Verrucomicrobiae 0.6 0.4 0.4 0.6 1.2 −10.6 2.9 4.4 3.1
(−0.4, 1.5) (0.1, 0.8) (−0.5, 1.2) (0.4, 0.8) (−0.1, 2.4) (−25.9, 4.8) (−13.0, 18.8) (0.1, 8.6) (−0.7, 6.9)
p = 0.195 p = 0.025 p = 0.303 p = 0.000 p = 0.058 p = 0.158 p = 0.696 p = 0.044 p = 0.097
R2 = 0.227 R2 = 0.534 R2 = 0.258 R2 = 0.850 R2 = 0.423 R2 = 0.173 R2 = 0.014 R2 = 0.319 R2 = 0.231
In each of the models, the associations are reported as absolute difference (β), with 95% Confidence Intervals (CI), in immune system parameters levels by 1 unit increase in gut
microbiota. In bold are reported the statistically significant results (p < 0.05). Per each of the models, the Coefficient of determination (R2 ) is also reported.
(conventional dendritic cells), and CD11b+CD11c-F4/80+ cells
(macrophages; Figure 3). In parallel, we measured by qPCR the
intra-tissue expression levels of the following panel of cytokines
that play a major role in the adaptive immune system being
secreted by helper CD4+ T cells (Th1, Th2, Th17, and Treg)
and stimulating several cell types: IL-1α, IL-4, IL-6, IL-12, IL-
17 and IFN-γ. IL-1α, IL-12, IL-17, and IFN-γ are generally
regarded as pro-inflammatory and pro-atherogenic, while IL-4
and IL-6 display pro- and anti-inflammatory properties which
are context-dependent (Hunter and Jones, 2015; Zarzycka et al.,
2015). Our analyses showed a great enrichment in myeloid cells,
CD45+, CD11b+, CD11c, F480+, Ly6G+ upon PD- in the
spleen compared to ND- and HD-feeding (Figure 4A), a massive
lymphocyte infiltration in the aorta and in the liver upon both PD
and HD compared to ND diet (Figure 4B), a significant increase
in CD4+ and CD8+ positive cells percentage exclusively in the
aorta and in the hearts of PD-fed animals compared to ND
and HD (Figure 4C); no changes were observed in abdominal
fat tissues (data not shown). At the cytokine level, IL-17 was
greatly increased in the aorta, heart and fat only in PD-fed
mice compared to HD and ND (Figure 5A). IL-1α, IFN-γ, and
IL-4 levels were augmented in the aorta and/or in the heart
only in PD-fed mice compared to HD and ND (Figures 5B,C).
Finally, we report a trend in increased IL-6 and IL-12 mRNA
levels in adipose tissue of PD mice compared to HD- and
ND-fed mice (Figure 5D). Collectively, our data surprisingly
indicate activation of several components of the adaptive
immune system in the metabolic syndrome lean PD mouse
model compared to an established mouse model of diet-induced
obesity.
Gut Microbiota Profiling By Metagenomic
Sequencing
The reciprocal interaction between the gut microbiota and the
adaptive immunity contributes to the insurgence of metabolic
diseases and of inflammation (Kato et al., 2014; Zhang and
Luo, 2015; Marchesi et al., 2016). It is however unknown how
this interplay adapts to the MSL or MHO clinical features. To
this aim we identified bacterial populations contained in fecal
samples from ND-, HD-, and PD-fed mice using next generation
high throughput sequencing of variable regions (V3–V4) of
the 16S rDNA bacterial gene (Lluch et al., 2015; Paisse et al.,
2016). Alpha diversity analyses, representing the mean of species
diversity in each sample showed that ND-fed mice had a higher
taxonomic diversity than the HD-fed mice, which in turn have
a higher taxonomic diversity than the PD-fed mice (Figure 6A).
Feces microbial composition after 20 weeks of different diet
is highly different between the three groups, as shown by
beta diversity metrics based multi-dimensional scaling Unifrac
analysis (Figure 7A) and by hierarchical clustering (Figure 7B).
The community structures observed in the different groups
were significantly different. At the phylum level, Firmicutes
and Bacteroidetes dominated the fecal microbiota in all groups
(Figure 7C). No differences of Firmicutes and Bacteroidetes
relative abundance were observed between ND and HD groups
(Figure 7C). However, an increase in Bacteroidetes and a
decrease in Firmicutes were observed in PD groups (Figure 6B).
At the family level, the fecal microbiota was dominated
by Porphyromonadaceae in all groups (Figure 7D) and are
significantly higher in Paigen Diet mice compared to HD and
ND groups (Figure 7F). Focusing on diet effect between the
three groups of mice, broad population changes were seen from
phylum to genus level (Figure 7E), significantly enriched taxa
for all groups are identified using LDA Effect Size (LEfSe)
analysis. Clostridia class are significantly enriched in ND and HD
mice compared to PD mice (Figures 7E,F). Actinobacteria and
Deltaproteobacteria are enriched in HD group compared to ND
and PD groups (Figures 7E,F). Bacteroidia and Verrucomicrobia
are enriched in PD group compared to ND and HD groups
(Figures 7E,F). Interestingly we have identified (with databank
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TABLE 3 | Associations from linear regression models between gut microbiota
and alterations of adaptive immune system parameters measured in the adipose
tissue.
IL-17 IL-12 IL-6
β (95% CI) β (95% CI) β (95% CI)
Actinobacteria −1.6 −1.6 −1.9
(−3.4, 0.1) (−2.9, −0.4) (−4.1, 0.2)
p = 0.065 p = 0.020 p = 0.071
R2 = 0.407 R2 = 0.564 R2 = 0.393
Alphaproteobacteria 0 0 0
(−0.4, 0.3) (−0.3, 0.3) (−0.5, 0.4)
p = 0.761 p = 0.841 p = 0.799
R2 = 0.014 R2 = 0.006 R2 = 0.010
Bacilli −0.1 −0.1 −0.1
(−0.4, 0.1) (−0.3, 0.2) (−0.5, 0.3)
p = 0.294 p = 0.470 p = 0.561
R2 = 0.155 R2 = 0.077 R2 = 0.050
Bacteroidia 0.02 0.02 0.04
(−0.01, 0.06) (−0.01, 0.05) (−0.00, 0.07)
p = 0.186 p = 0.093 p = 0.072
R2 = 0.235 R2 = 0.350 R2 = 0.390
Betaproteobacteria 5.1 3.7 4.4
(3.0, 7.2) (1.0, 6.4) (−0.2, 9.1)
p = 0.001 p = 0.014 p = 0.058
R2 = 0.830 R2 = 0.599 R2 = 0.423
Clostridia 0 0 0
(−0.1, 0.0) (−0.1, 0.0) (−0.1, 0.0)
p = 0.315 p = 0.185 p = 0.148
R2 = 0.143 R2 = 0.236 R2 = 0.274
Deferribacteres −0.4 −0.3 −0.3
(−2.3, 1.5) (−1.9, 1.3) (−2.6, 2.0)
p = 0.633 p = 0.660 p = 0.739
R2 = 0.034 R2 = 0.029 R2 = 0.017
Deltaproteobacteria −0.1 0 0.1
(−0.4, 0.3) (−0.3, 0.3) (−0.3, 0.5)
p = 0.685 p = 0.905 p = 0.525
R2 = 0.025 R2 = 0.002 R2 = 0.060
Erysipelotrichia −0.5 −0.4 −0.5
(−1.8, 0.7) (−1.5, 0.7) (−2.1, 1.0)
p = 0.367 p = 0.412 p = 0.452
R2 = 0.117 R2 = 0.098 R2 = 0.083
Gammaproteobacteria 0.4 −2.6 −2.5
(−7.3, 8.0) (−8.7, 3.5) (−11.5, 6.6)
p = 0.908 p = 0.346 p = 0.540
R2 = 0.002 R2 = 0.127 R2 = 0.056
Mollicutes 0 −0.1 −0.1
(−0.3, 0.2) (−0.3, 0.2) (−0.4, 0.2)
p = 0.840 p = 0.580 p = 0.471
R2 = 0.006 R2 = 0.046 R2 = 0.077
(Continued)
TABLE 3 | Continued
IL-17 IL-12 IL-6
β (95% CI) β (95% CI) β (95% CI)
Multi-affiliation −0.8 −0.6 −0.7
(−1.8, 0.2) (−1.5, 0.3) (−2.1, 0.7)
p = 0.111 p = 0.157 p = 0.252
R2 = 0.321 R2 = 0.264 R2 = 0.182
Negativicutes 0.7 −0.4 −0.1
(−1.8, 3.2) (−2.6, 1.7) (−3.2, 3.1)
p = 0.550 p = 0.654 p = 0.965
R2 = 0.053 R2 = 0.030 R2 = 0.000
Verrucomicrobiae 0.3 0.2 0.2
(0.1, 0.5) (−0.1, 0.4) (−0.2, 0.6)
p = 0.022 p = 0.106 p = 0.258
R2 = 0.551 R2 = 0.330 R2 = 0.178
In each of the models, the associations are reported as absolute difference (β), with 95%
Confidence Intervals (CI), in immune system parameters levels by 1 unit increase in gut
microbiota. In bold are reported the statistically significant results (p < 0.05). Per each of
the models, the Coefficient of determination (R2 ) is also reported.
RDP v11.4) an increase in Akkermansia muciniphila and
Bacteroides dorei in PD groups compared to HD and ND
groups (Figure 6C). Therefore, the most striking result of our
metagenomic analyses in gut microbiota composition between
the MSL and MHO mimicking diets (PD and HD, respectively)
is the preponderance of Bacteroidia and Verrucomicrobia in PD
compared to HD and control ND.
Association of Gut Microbiota Profile with
Adaptive Immune Factors
We then sought to explore correlation between changes in gut
microbiota composition with the over-responses of the adaptive
immune system in mice, irrespective of the diet administered,
using linear regression. The associations from regression analyses
between gut microbiota classes and cytokines or immune
cell types are shown in full in Tables 1–5. Some statistically
significant associations were observed in each of the organs
analyzed (aorta, heart, adipose tissue, liver, and spleen). For
example (1) a linear increase in Bacteroidia and a decrease
in Clostridiae were associated to an increase in IL-17, IFN-γ,
IL-4, and CD8+ cells in the aorta. A decrease in Mollicutes
and an increase in Verrucomicrobia was associated to increased
infiltration of leukocytes (CD45+) as well as CD4+ and in CD8+
T cells and to an increase in IL-17, in the aorta (Table 1); (2) A
linear increase in Bacteroidia and a decrease in Clostridiae was
associated to an increase in IFN-γ, IL-6, lymphocytes, and CD4+
cells in the heart. An increase in Verrucomicrobia was associated
to increased CD45+ cells and lymphocytes and to an increase
in IL-1a, IFN-γ, and in CD4+ cells in the heart (Table 2). (3)
A linear decrease in Actinobacteria and in Betaproteobacteria
was associate to an increase in IL-6 and/or in IL-12 in the
adipose tissue (Table 3). An increase in Verrucomicrobia was
associated to increased IL-17 in the adipose tissue (Table 3). (4)
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TABLE 4 | Associations from linear regression models between gut microbiota and alterations of adaptive immune system parameters measured in the liver.
Myeloid cells Lymphocytes CD4+ CD8+ CD45+ CD11b+ CD11c+ F480+ Ly6G+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Actinobacteria −14.9 −6.3 0.5 0.6 0.4 −25.6 10.4 −36.5 −70.7
(−67.9, 38.1) (−128.4, 115.7) (−18.9, 19.9) (−10.9, 12.1) (−70.6, 71.4) (−55.4, 4.1) (−32.8, 53.7) (−77.9, 4.9) (−167.3, 26.0)
p = 0.549 p = 0.911 p = 0.952 p = 0.912 p = 0.991 p = 0.085 p = 0.606 p = 0.079 p = 0.136
R2 = 0.034 R2 = 0.001 R2 = 0.000 R2 = 0.001 R2 = 0.000 R2 = 0.246 R2 = 0.025 R2 = 0.255 R2 = 0.191
Alphaproteobacteria 5.7 8.8 0.9 0.7 4.1 1.4 1.8 −1.8 −12.7
(−2.4, 13.9) (−10.7, 28.3) (−2.3, 4.1) (−1.2, 2.6) (−7.4, 15.6) (−4.3, 7.0) (−5.4, 9.0) (−9.7, 6.1) (−28.5, 3.0)
p = 0.148 p = 0.341 p = 0.539 p = 0.421 p = 0.444 p = 0.601 p = 0.587 p = 0.627 p = 0.103
R2 = 0.180 R2 = 0.083 R2 = 0.035 R2 = 0.060 R2 = 0.054 R2 = 0.026 R2 = 0.028 R2 = 0.022 R2 = 0.223
Bacilli 2.3 −0.8 −0.2 −0.1 −1.4 0.5 0.4 −1.5 −6.3
(−5.3, 9.9) (−18.3, 16.7) (−3.0, 2.6) (−1.7, 1.6) (−11.5, 8.7) (−4.4, 5.4) (−5.8, 6.7) (−8.3, 5.3) (−21.1, 8.5)
p = 0.516 p = 0.922 p = 0.863 p = 0.901 p = 0.765 p = 0.814 p = 0.884 p = 0.644 p = 0.367
R2 = 0.039 R2 = 0.001 R2 = 0.003 R2 = 0.002 R2 = 0.009 R2 = 0.005 R2 = 0.002 R2 = 0.020 R2 = 0.074
Bacteroidia 1.2 1.6 0.2 0.1 0.8 0.6 0.2 0.5 −0.7
(0.7, 1.6) (−0.0, 3.3) (−0.1, 0.5) (−0.1, 0.3) (−0.2, 1.8) (0.2, 1.0) (−0.5, 0.9) (−0.3, 1.2) (−2.4, 0.9)
P<0.001 p = 0.054 p = 0.172 p = 0.264 p = 0.115 p = 0.004 p = 0.490 p = 0.183 p = 0.359
R2 = 0.773 R2 = 0.297 R2 = 0.163 R2 = 0.112 R2 = 0.210 R2 = 0.551 R2 = 0.044 R2 = 0.155 R2 = 0.077
Betaproteobacteria 51.6 115.5 14.1 5.6 55.2 38.3 40.9 11.6 −33.2
(−21.3, 124.5) (−50.0, 281.0) (−13.3, 41.6) (−11.2, 22.5) (−44.4, 154.7) (−6.2, 82.7) (−18.6, 100.4) (−59.6, 82.8) (−192.2, 125.7)
p = 0.148 p = 0.153 p = 0.281 p = 0.478 p = 0.248 p = 0.085 p = 0.159 p = 0.727 p = 0.654
R2 = 0.180 R2 = 0.177 R2 = 0.105 R2 = 0.047 R2 = 0.119 R2 = 0.246 R2 = 0.172 R2 = 0.012 R2 = 0.019
Clostridia −1.3 −1.9 −0.2 −0.1 −0.9 −0.6 −0.3 −0.3 1
(−1.8, −0.8) (−3.7, −0.1) (−0.5, 0.1) (−0.3, 0.1) (−2.0, 0.2) (−1.1, −0.1) (−1.1, 0.4) (−1.2, 0.5) (−0.8, 2.8)
p<0.001 p = 0.044 p = 0.169 p = 0.234 p = 0.099 p = 0.019 p = 0.369 p = 0.379 p = 0.234
R2 = 0.755 R2 = 0.319 R2 = 0.164 R2 = 0.126 R2 = 0.228 R2 = 0.406 R2 = 0.074 R2 = 0.071 R2 = 0.126
Deferribacteres −50.6 −66.7 −10.1 −6.6 −37.3 −29.3 −5.6 −20 44
(−80.6, −20.6) (−158.6, 25.1) (−24.9, 4.6) (−15.2, 2.0) (−91.2, 16.6) (−50.3, −8.4) (−42.0, 30.8) (−57.8, 17.8) (−40.9, 128.8)
p = 0.003 p = 0.138 p = 0.159 p = 0.120 p = 0.156 p = 0.011 p = 0.741 p = 0.269 p = 0.278
R2 = 0.555 R2 = 0.189 R2 = 0.172 R2 = 0.205 R2 = 0.174 R2 = 0.463 R2 = 0.010 R2 = 0.110 R2 = 0.106
Deltaproteobacteria 0.9 10.6 1.7 0.9 6.3 −2.8 1.2 −3.8 −10.1
(−6.9, 8.6) (−5.4, 26.6) (−0.8, 4.3) (−0.6, 2.5) (−3.0, 15.6) (−7.4, 1.7) (−5.0, 7.5) (−10.2, 2.6) (−24.0, 3.8)
p = 0.812 p = 0.173 p = 0.165 p = 0.201 p = 0.165 p = 0.201 p = 0.672 p = 0.219 p = 0.137
R2 = 0.005 R2 = 0.162 R2 = 0.168 R2 = 0.144 R2 = 0.167 R2 = 0.144 R2 = 0.017 R2 = 0.134 R2 = 0.190
Erysipelotrichia −23.4 −48.7 −7.2 −3.6 −26.3 −11.8 −0.1 −11.1 28.4
(−52.9, 6.1) (−117.0, 19.6) (−18.2, 3.9) (−10.3, 3.2) (−66.6, 14.0) (−31.5, 7.9) (−27.2, 27.0) (−39.9, 17.6) (−35.3, 92.1)
p = 0.109 p = 0.145 p = 0.181 p = 0.267 p = 0.179 p = 0.215 p = 0.996 p = 0.412 p = 0.348
R2 = 0.216 R2 = 0.183 R2 = 0.157 R2 = 0.111 R2 = 0.158 R2 = 0.136 R2 = 0.000 R2 = 0.062 R2 = 0.080
Gammaproteobacteria 13.6 123.7 30.8 16.7 86.8 −11.7 −0.3 −27.4 −100.9
(−85.3, 112.6) (−85.7, 333.0) (1.5, 60.1) (−1.5, 34.8) (−30.6, 204.2) (−74.4, 50.9) (−81.0, 80.3) (−113.8, 59.1) (−287.0, 85.3)
p = 0.767 p = 0.220 p = 0.041 p = 0.068 p = 0.132 p = 0.688 p = 0.993 p = 0.501 p = 0.258
R2 = 0.008 R2 = 0.133 R2 = 0.327 R2 = 0.271 R2 = 0.194 R2 = 0.015 R2 = 0.000 R2 = 0.042 R2 = 0.115
Mollicutes −6 −10.7 −1.7 −1.2 −6.2 −2.9 −0.5 −1.4 8
(−11.2, −0.8) (−23.7, 2.3) (−3.8, 0.4) (−2.3, −0.0) (−13.8, 1.4) (−6.6, 0.7) (−5.8, 4.8) (−7.1, 4.4) (−3.9, 19.9)
p = 0.028 p = 0.098 p = 0.098 p = 0.049 p = 0.099 p = 0.107 p = 0.838 p = 0.610 p = 0.169
R2 = 0.370 R2 = 0.229 R2 = 0.229 R2 = 0.308 R2 = 0.228 R2 = 0.219 R2 = 0.004 R2 = 0.024 R2 = 0.165
(Continued)
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TABLE 4 | Continued
Myeloid cells Lymphocytes CD4+ CD8+ CD45+ CD11b+ CD11c+ F480+ Ly6G+
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Multi−affiliation −2.6 9.6 2.1 1.3 8.3 0.7 −1.4 −1.2 −4
(−16.5, 11.4) (−21.6, 40.7) (−2.7, 7.0) (−1.6, 4.2) (−9.3, 26.0) (−8.2, 9.6) (−12.8, 9.9) (−13.7, 11.2) (−31.8, 23.9)
p = 0.693 p = 0.513 p = 0.355 p = 0.333 p = 0.321 p = 0.869 p = 0.788 p = 0.831 p = 0.758
R2 = 0.015 R2 = 0.040 R2 = 0.078 R2 = 0.085 R2 = 0.089 R2 = 0.003 R2 = 0.007 R2 = 0.004 R2 = 0.009
Negativicutes 23.9 35.5 6.8 −2.2 25.8 10.6 −11.8 31.1 8.6
(−37.8, 85.5) (−106.6, 177.6) (−15.7, 29.3) (−15.8, 11.3) (−56.2, 107.8) (−29.2, 50.4) (−62.9, 39.2) (−21.6, 83.8) (−118.0, 135.2)
p = 0.412 p = 0.593 p = 0.519 p = 0.723 p = 0.503 p = 0.568 p = 0.621 p = 0.221 p = 0.884
R2 = 0.062 R2 = 0.027 R2 = 0.039 R2 = 0.012 R2 = 0.042 R2 = 0.030 R2 = 0.023 R2 = 0.133 R2 = 0.002
Verrucomicrobiae 7.9 15 1.6 1 8.4 4.1 1.8 3.8 −6.1
(1.9, 14.0) (−0.3, 30.2) (−1.1, 4.3) (−0.5, 2.6) (−0.6, 17.4) (−0.3, 8.4) (−4.6, 8.2) (−2.9, 10.5) (−21.6, 9.3)
p = 0.015 p = 0.053 p = 0.214 p = 0.178 p = 0.065 p = 0.063 p = 0.551 p = 0.241 p = 0.401
R2 = 0.429 R2 = 0.299 R2 = 0.137 R2 = 0.159 R2 = 0.276 R2 = 0.281 R2 = 0.033 R2 = 0.123 R2 = 0.065
In each of the models, the associations are reported as absolute difference (β), with 95% Confidence Intervals (CI), in immune system parameters levels by 1 unit increase in gut
microbiota. In bold are reported the statistically significant results (p < 0.05). Per each of the models, the Coefficient of determination (R2 ) is also reported.
A linear increase in Bacteroidia and a decrease in Clostridiae
were associated to increased myeloid cells and CD11b+ cells
in the liver. Also a decrease in Mollicutes and an increase in
Verrucomicrobia was associated to increased myeloid cells in
the liver (Table 4). (5) A linear increase in Bacteroidia and in
Verrucomicrobia, and a decrease in Clostridiae, were associated
to increased myeloid cell markers CD11b+, CD11c+, F4/90+,
and Ly6G+ cells in the spleen (Table 5).
DISCUSSION
The results of our study in mice suggest that diet composition
might have a pervasive role in co-regulating adaptive immunity
and gut microbiota’s profile in healthy obese subjects and
in atherogenesis/inflammation in subjects with normal BMI.
There has been recently a great focus on a particular subset
of overweight and obese individuals having normal metabolic
profile despite highly increased adipose mass (MHO=metabolic
healthy obese; Karelis, 2008; Flegal et al., 2013). Individuals
with adverse metabolic status despite a normal BMI have also
been described (MSL = metabolic syndrome lean; Karelis, 2008;
Flegal et al., 2013). It is currently unclear whether metabolic
dysfunctions affects the higher morbidity and mortality observed
in individuals with higher BMI: the concept of “benign obesity”
has been challenged by some meta-analyses (Kramer et al., 2013)
but not by others (Dhana et al., 2016), suggesting that MetS and
not elevated BMI is an unequivocal risk factor for cardiovascular
diseases (CVD). As it was previously reported, we confirmed
that mice in a C57/BL6 genetic background fed a Paigen diet
(PD) developed features of MetS, including hyperinsulinemia,
hyperglycaemia, steatohepatitis, and inflammatory infiltration
into the aorta, without increase in body weight (Getz and
Reardon, 2006). Although, atherosclerosis is not observed
without ApoE−/− mutation in mice, this study reports for
the first time a systemic activation of the immune system
upon an atherogenic diet, with high tissue infiltration of
myeloid cell subsets CD45+CD11b+CD11c, CD45+ F4/80+,
CD45+ CD11b+Ly6G+ in the spleen, a massive lymphocyte
infiltration in the aorta and in the liver, a significant increase
in CD4+ and CD8+ positive cells in the aorta and in the
hearts, paralleled by increased IL-17, IL-1, IFN-γ, and IL-
4 levels in the aorta and heart. The elevated level of gene
expression for IL-1α detected in the heart might indicate
the activation of myeloid cell types, probably macrophages,
which have been described as the main proinflammatory cell
population in atherosclerotic plaques (Jonasson et al., 1986),
and also play a crucial role in the development of heart failure
(Heidt et al., 2014). In general, IL-1 critically orchestrates
the inflammatory events that are considered building blocks
for the formation atherosclerotic plaques, precursors and risk
factor for CVD such as myocardial infarction (Van Tassell
et al., 2013; Gallego-Colon et al., 2015; Taleb et al., 2015).
In this study, mice in a C57/BL6 genetic background fed a
high fat diet (HD) developed obesity, increased body weight
and fatty liver without systemic inflammation and activation of
the adaptive immune system. We took advantage of these two
phenotypically characterized mice models of MSL and MHO, to
scrutinize the composition of gut microbiota in the stool of these
metabolic exceptions. High-throughput 16S targeted sequencing
showed a dominion of Bacteroidia, Deltaproteobacteria and
Verrucomicrobia and under-representation of Clostridia in MSL
PD-fed mice. Generally, Proteobacteria and Verrucomicrobia
are not abundant in the healthy gut, but abundant in the gut
dysbiosis of patients with type 2 diabetes or with inflammatory
bowel disease (IBD) (Larsen et al., 2010; Qin et al., 2012; Shin
et al., 2015). More abundant bacteria such as Bacteroidiales and
Clostridiales are more and less represented, respectively, in type
2 diabetes compared to obesity (Larsen et al., 2010; Qin et al.,
2012). Bacteroidiales are associated to weight loss (Million et al.,
2013). Our results are completely in line with the above reports
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TABLE 5 | Associations from linear regression models between gut microbiota and alterations of adaptive immune system parameters measured in the spleen.
IL-17 IFNg Myeloid cells CD45+ CD11b+ CD11c+ F480+ Ly6G
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Actinobacteria −0.4 −2.5 −7.3 −6.4 −5.2 −1.1 −1.8 −3.9
(−14.5, 13.7) (−18.6, 13.6) (−21.0, 6.4) (−17.1, 4.4) (−13.9, 3.6) (−2.6, 0.5) (−4.9, 1.4) (−9.7, 2.0)
p = 0.947 p = 0.726 p = 0.267 p = 0.220 p = 0.220 p = 0.155 p = 0.240 p = 0.171
R2 = 0.001 R2 = 0.019 R2 = 0.111 R2 = 0.134 R2 = 0.133 R2 = 0.175 R2 = 0.123 R2 = 0.163
Alphaproteobacteria −0.9 −0.8 0.3 0.3 0.2 0.1 0 0.1
(−3.0, 1.2) (−3.3, 1.6) (−2.1, 2.7) (−1.7, 2.2) (−1.4, 1.7) (−0.2, 0.3) (−0.5, 0.6) (−0.9, 1.2)
p = 0.349 p = 0.454 p = 0.769 p = 0.771 p = 0.826 p = 0.671 p = 0.877 p = 0.807
R2 = 0.126 R2 = 0.082 R2 = 0.008 R2 = 0.008 R2 = 0.005 R2 = 0.017 R2 = 0.002 R2 = 0.006
Bacilli 0.1 −0.6 −0.5 −0.4 −0.3 0 −0.1 −0.2
(−1.8, 2.0) (−2.7, 1.6) (−2.5, 1.6) (−2.0, 1.2) (−1.7, 1.0) (−0.3, 0.2) (−0.6, 0.3) (−1.1, 0.7)
p = 0.912 p = 0.547 p = 0.615 p = 0.602 p = 0.598 p = 0.688 p = 0.570 p = 0.588
R2 = 0.002 R2 = 0.054 R2 = 0.024 R2 = 0.026 R2 = 0.026 R2 = 0.015 R2 = 0.030 R2 = 0.028
Bacteroidia −0.1 −0.2 0.2 0.2 0.1 0 0.1 0.1
(−0.3, 0.1) (−0.4, 0.1) (0.0, 0.4) (0.0, 0.3) (0.0, 0.3) (0.0, 0.0) (0.0, 0.1) (0.0, 0.2)
p = 0.362 p = 0.217 p = 0.020 p = 0.015 p = 0.015 p = 0.005 p = 0.021 p = 0.011
R2 = 0.120 R2 = 0.208 R2 = 0.402 R2 = 0.432 R2 = 0.429 R2 = 0.519 R2 = 0.399 R2 = 0.459
Betaproteobacteria −16.2 −18.6 14 11.8 9.5 1.9 3.1 6.2
(−43.6, 11.2) (−50.1, 12.9) (−5.7, 33.6) (−3.5, 27.2) (−3.1, 22.0) (−0.3, 4.1) (−1.4, 7.7) (−2.4, 14.8)
p = 0.204 p = 0.206 p = 0.146 p = 0.118 p = 0.125 p = 0.082 p = 0.159 p = 0.140
R2 = 0.219 R2 = 0.217 R2 = 0.182 R2 = 0.207 R2 = 0.200 R2 = 0.249 R2 = 0.172 R2 = 0.187
Clostridia 0.2 0.1 −0.2 −0.2 −0.2 0 −0.1 −0.1
(−0.1, 0.4) (−0.2, 0.4) (−0.4, −0.0) (−0.4, −0.0) (−0.3, −0.0) (−0.1, −0.0) (−0.1, −0.0) (−0.2, −0.0)
p = 0.157 p = 0.410 p = 0.025 p = 0.019 p = 0.021 p = 0.007 p = 0.029 p = 0.015
R2 = 0.264 R2 = 0.099 R2 = 0.379 R2 = 0.405 R2 = 0.396 R2 = 0.493 R2 = 0.363 R2 = 0.429
Deferribacteres 1.3 4.9 −6.6 −5.2 −4.5 −0.8 −1.6 −3
(−10.4, 13.0) (−7.9, 17.7) (−17.9, 4.8) (−14.2, 3.7) (−11.7, 2.8) (−2.1, 0.5) (−4.2, 1.0) (−7.9, 2.0)
p = 0.802 p = 0.396 p = 0.228 p = 0.226 p = 0.204 p = 0.199 p = 0.204 p = 0.213
R2 = 0.010 R2 = 0.105 R2 = 0.129 R2 = 0.130 R2 = 0.142 R2 = 0.145 R2 = 0.142 R2 = 0.137
Deltaproteobacteria −1.5 0.5 0.1 0 −0.1 0 0 0
(−3.2, 0.2) (−2.0, 3.0) (−2.0, 2.1) (−1.6, 1.7) (−1.4, 1.3) (−0.2, 0.3) (−0.5, 0.4) (−0.9, 0.9)
p = 0.083 p = 0.641 p = 0.945 p = 0.950 p = 0.933 p = 0.918 p = 0.879 p = 0.962
R2 = 0.369 R2 = 0.033 R2 = 0.001 R2 = 0.000 R2 = 0.001 R2 = 0.001 R2 = 0.002 R2 = 0.000
Erysipelotrichia −1.8 9 −3.9 −3.2 −2.6 −0.5 −1 −1.8
(−9.9, 6.3) (4.0, 14.0) (−12.5, 4.7) (−10.0, 3.6) (−8.2, 2.9) (−1.5, 0.5) (−2.9, 1.0) (−5.6, 2.0)
p = 0.612 p = 0.004 p = 0.336 p = 0.320 p = 0.321 p = 0.321 p = 0.301 p = 0.323
R2 = 0.039 R2 = 0.723 R2 = 0.084 R2 = 0.090 R2 = 0.089 R2 = 0.089 R2 = 0.097 R2 = 0.089
Gammaproteobacteria −15.7 −7.6 −0.1 −1.1 −0.8 −0.5 −0.1 −1.7
(−60.9, 29.6) (−61.7, 46.4) (−26.9, 26.6) (−22.4, 20.1) (−18.0, 16.5) (−3.6, 2.6) (−6.3, 6.1) (−13.4, 10.0)
p = 0.440 p = 0.749 p = 0.991 p = 0.909 p = 0.926 p = 0.745 p = 0.975 p = 0.755
R2 = 0.087 R2 = 0.016 R2 = 0.000 R2 = 0.001 R2 = 0.001 R2 = 0.010 R2 = 0.000 R2 = 0.009
Mollicutes 0.9 −0.1 −0.6 −0.5 −0.3 −0.1 −0.1 −0.2
(−0.5, 2.3) (−2.0, 1.8) (−2.3, 1.1) (−1.9, 0.9) (−1.5, 0.8) (−0.3, 0.1) (−0.5, 0.3) (−1.0, 0.5)
p = 0.168 p = 0.908 p = 0.440 p = 0.442 p = 0.509 p = 0.349 p = 0.573 p = 0.505
R2 = 0.252 R2 = 0.002 R2 = 0.055 R2 = 0.055 R2 = 0.041 R2 = 0.080 R2 = 0.030 R2 = 0.042
(Continued)
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TABLE 5 | Continued
IL-17 IFNg Myeloid cells CD45+ CD11b+ CD11c+ F480+ Ly6G
β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI)
Multi−affiliation 0.3 8 −0.9 −0.7 −0.7 −0.1 −0.2 −0.4
(−7.5, 8.1) (2.5, 13.5) (−4.7, 2.8) (−3.7, 2.2) (−3.1, 1.7) (−0.6, 0.3) (−1.1, 0.7) (−2.0, 1.3)
p = 0.921 p = 0.011 p = 0.599 p = 0.593 p = 0.515 p = 0.469 p = 0.614 p = 0.614
R2 = 0.002 R2 = 0.629 R2 = 0.026 R2 = 0.027 R2 = 0.039 R2 = 0.049 R2 = 0.024 R2 = 0.024
Negativicutes −5.5 −5.8 14.5 10.8 9.1 1.3 3.3 5.5
(−20.7, 9.6) (−23.4, 11.8) (0.3, 28.7) (−0.8, 22.4) (−0.1, 18.4) (−0.4, 3.1) (0.0, 6.6) (−1.1, 12.1)
p = 0.418 p = 0.464 p = 0.045 p = 0.064 p = 0.053 p = 0.128 p = 0.048 p = 0.094
R2 = 0.096 R2 = 0.079 R2 = 0.316 R2 = 0.278 R2 = 0.300 R2 = 0.198 R2 = 0.310 R2 = 0.234
Verrucomicrobiae −1.6 −1.1 2.1 1.7 1.4 0.3 0.5 0.9
(−3.2, −0.0) (−3.4, 1.1) (0.5, 3.8) (0.5, 3.0) (0.3, 2.4) (0.1, 0.4) (0.1, 0.9) (0.2, 1.7)
p = 0.048 p = 0.274 p = 0.015 p = 0.012 p = 0.016 p = 0.008 p = 0.024 p = 0.015
R2 = 0.451 R2 = 0.167 R2 = 0.431 R2 = 0.449 R2 = 0.422 R2 = 0.488 R2 = 0.385 R2 = 0.429
In each of the models, the associations are reported as absolute difference (β), with 95% Confidence Intervals (CI), in immune system parameters levels by 1 unit increase in gut
microbiota. In bold are reported the statistically significant results (p < 0.05). Per each of the models, the Coefficient of determination (R2 ) is also reported.
and with the strong pro-inflammatory and pro-MetS role of PD
compared to ND and HD. To our knowledge, a limited number
of studies described clearly a role for gut microbiota in the onset
of the MHO phenotype. It has been shown that separate cohorts
of mice belonging to the same genetic background (C57/BL6)
became either diabetic or resistant to diabetes and related
metabolic dysfunctions despite being eating the same high-fat
diet triggering obesity (Serino et al., 2012). The gut microbiota
of the diabetes-resistant mice displayed a 20% decrease in
the abundance of Firmicutes that were replaced by a parallel
increase in Bacteriodetes (Serino et al., 2012). Moreover, the
microbiota of diabetes-resistant mice presented with less bacteria
of the helicobacter genus compared to the diabetic mice; instead,
actinobacteria levels were unchanged (Serino et al., 2012). Our
and these published studies suggest that the gut microbiota
might reflect faithfully the metabolic phenotype irrespective of
variability in the genetic background and diets of the host. Results
of a recent study performed in the brown bear (Ursus arctos) are
consistent with this (Sommer et al., 2016). The bear is a mammal
accumulating enormous quantities of adipose fat in a seasonal
manner (summer); by doing so, bears develop hyperlipidemia
while maintaining metabolic health and being resistant to the
development of atherosclerosis (Arinell et al., 2012). In fact,
during summer season, the gut of bears harbored a different
composition ofmicrobiota than during winter season. In summer
it was shown that gut microbiota was richer in Actinobacteria,
Firmicutes, Proteobacteria, and poorer in Bacteroidetes (Sommer
et al., 2016).
Several groups have provided data supporting a role
for gut microbiota in the establishment of the MSL. If
intestinal microbiota is suppressed in atherosclerosis-prone
mice, an inhibition of dietary-choline-dependent atherosclerosis
is observed (Wang et al., 2011). Patients with symptomatic
atherosclerosis and normal body weight showed enrichment of
the genus Collinsella of Actinobacteria in the gut (Karlsson et al.,
2012). Generally, gut microbiota can affect atherosclerosis even
in absence obesity or high fat feeding by different pathways:
(i) infection activating the immune system and causing an
inflammatory and proatherogenic response at distant sites; (ii)
alteration of the levels of serum triglycerides and cholesterol, and
of the metabolism of bile acids; (iii) dietary components (such
as choline) and microbial metabolites [such as trimethylamine
N-oxide (TMAO) generated from microbial metabolism of
phosphatidylcholine, which is common in redmeat and shellfish]
lead to the production of both beneficial and harmful molecules
(Jonsson and Backhed, 2017). For this reasons, gut microbiome
is sometimes described as “endocrine” organ contributing to
organism homeostasis [47].
Here, observed pro-inflammatory cytokines levels and tissue
infiltrates correlating with decreased numbers of Clostridia
corroborate previous findings on their regulatory functions.
Clostridia strains presented in colon environment synergise
to induce Tregs development [48, 49]. Tregs are fundamental
to maintain mucosal homeostasis; therefore their insufficient
development has pathological potential. Atherosclerosis develops
upon stimulation of dendritic cells with oxidized low-density
lipoproteins, the pathology is orchestrated by Th17 produced
IL-17 [50], pro-autoimmune role of Th17 in atherosclerosis as
well as association to HD induced chronic inflammation is well-
described. Bacteroidetes has been associated to “healthy” non-
obese homeostatic microbiome and with immunomodulation
[51]. Interestingly addition of short chain fatty acids to the diet
can result in Bacteroidetes abundance also during HD [52].
Bacteroides fragilis polysaccharide A (PSA) promotes T cells
development [53], furthermore dysbiosis is frequently described
as reduced Firmicutes/Bacteroidetes ratio, and this change was
associated with IL-17 production and Th17 responses [54, 55].
Our result shows that increase proportion of
Verrucomicrobiae correlates with higher percentage of myeloid
cells markers. Interestingly, Roopchand et al. has shown that
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presence of A. muciniphila from Verrucomicrobiae together
with presence of Bacteroidetes has significant role in protection
to diet-induced obesity and metabolic dysbiosis in mice fed with
HD [56]. Furthermore, in support to our data Ganesh et al.
showed that presence of A. muciniphila increased levels of IL-17
in Salmonella infected mice [57].
It has been already demonstrated that diet shapes gut
microbiome composition (De Filippo et al., 2010), and it is
also now recognized that commensal microorganisms impact
host gene expression not only in the gastrointestinal tract but
also in other systems (Levy et al., 2015). Moreover, microbial
cell components and secreted intermediate metabolites appear
to be implicated in the response of the host to microbial
colonization at the level of gene expression, which in turn
reciprocally influence the disease progression. Noteworthy, both
immunosuppressive drugs and probiotics affect the balance
between microbiota and the immune system (Bartman et al.,
2015). Particularly, probiotics supplementation have been shown
to be effective in restoring and/or renovating the microbiota
changes stimulating a number of health benefits, nevertheless
whether modulation of gastrointestinal microbiota composition
could have an effect on the amelioration of metabolic
syndrome in obese or lean subjects, remains to be further
investigated.
Supporting the link between metagenomics and
immunogenomics, our data underline that understanding
the reciprocal cross-talk between host immunity and microbiota
will pave the way to the development of new therapeutic
strategies against microbiome-driven common diseases, such as
the metabolic syndrome.
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